Engineered 3-D Human Liver Tissue for Hepatitis Studies
用于肝炎研究的工程 3D 人类肝脏组织
基本信息
- 批准号:6803105
- 负责人:
- 金额:$ 29.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-30 至 2006-09-30
- 项目状态:已结题
- 来源:
- 关键词:bioengineering /biomedical engineeringbiomarkerclinical researchdisease /disorder modelhepatitishepatitis C virushepatitis D virusimmunocytochemistryliver infectionmodel design /developmentnorthern blottingsorgan culturepolymerase chain reactiontechnology /technique developmenttissue engineeringtransfectionvirus replicationwestern blottings
项目摘要
DESCRIPTION (provided by applicant): The Hepatitis C virus (HCV) is a leading cause of liver disease for which current treatments are inadequate. Worldwide, 170 million are infected with HCV and the disease is projected to kill more people than AIDS within a few years based on a death rate that is likely to triple in the next 20 years. HCV infection of the liver progresses to cirrhosis followed by hepatocellular carcinoma and ultimately liver failure, and is the leading reason for liver transplantation. Such infections have become an increasingly appreciated public health problem, especially because current treatment modalities are inadequate. The current standard of care employs a combination of interferon-a and ribavirin, but only half of the patients treated show a sufficient antiviral response. Thus, clearly there is a need and market for better therapies.
A critical prerequisite for identifying and developing better therapies for viral hepatitis is the availability of convenient model systems capable of supporting efficient authentic viral replication. Unfortunately, to date the only non-human animal models are the chimpanzee and, with a variety of severe limitations, an immunodeficient xenotransplant mouse model. The great expense, and non-physiologic and low replication levels, respectively, associated with these animal models place great practical limits on their usefulness for rapid and efficient drug discovery and development. The availability of engineered human liver tissue capable of supporting viral infection would be relatively inexpensive, convenient, and ideal for the evaluation of novel antiviral therapies and the study of HCV and other virus-related pathology.
This proposal seeks to leverage patented breakthrough technology in the field of engineered, 3-dimensional liver tissue into a novel platform for molecular virology and antiviral development. Keys to the success of this technology include its scalability, reproducibility, and an established ability to yield liver tissues far exceeding previous attempts at organ engineering. We seek to determine whether the engineered tissues can be infected with an efficient hepatitis virus capable of high-level replication and for which highly sensitive and specific detection reagents are available, namely hepatitis delta virus (HDV). We will then extend the potential of this core technology by determining the level of hepatitis C virus (HCV) infection and replication supported by these tissues. Engineered liver tissues will be inoculated with HDV or HCV infectious serum, or transfected with RNA transcribed from an infectious clone. Immunohistochemistry, immunoblot analysis, RNA genome replication by strand-specific northern blots, and de novo produced virus release by serial passaging and quantitative PCR analyses of the media supernatant will determine if infection and replication have occurred. The project detailed in this proposal is designed to test the above hypotheses and translate the results into a valuable new model system for studying viral hepatitis, generating virus for research use and the development of antivirals. Future indications include a unique and invaluable reagent for studying many key aspects of these viral life cycles, their associated pathogenesis, and novel approaches to antiviral therapy, including determination of the infection potential of subsets of hepatic cells, as well as other liver diseases such as non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, hepatic fibrosis, and hepatocellular cancer (HCC).
描述(由申请人提供):丙型肝炎病毒(丙型肝炎病毒)是目前治疗不充分的肝病的主要原因。在全球范围内,有1.7亿人感染了丙型肝炎病毒,根据死亡率可能在未来20年内增加两倍的预测,这种疾病在几年内导致的死亡人数将超过艾滋病。肝脏的丙型肝炎病毒感染进展为肝硬变,随后是肝细胞癌,最终导致肝功能衰竭,是肝移植的主要原因。这类感染已成为一个日益受到重视的公共卫生问题,特别是因为目前的治疗方式不够充分。目前的治疗标准采用了干扰素-a和利巴韦林的组合,但只有一半的接受治疗的患者表现出足够的抗病毒反应。因此,显然存在对更好疗法的需求和市场。
确定和开发更好的病毒性肝炎治疗方法的关键前提是能够支持有效、真实的病毒复制的方便的模型系统的可用性。不幸的是,到目前为止,只有黑猩猩和免疫缺陷的异种移植小鼠模型是唯一的非人类动物模型。与这些动物模型相关的巨大费用、非生理学水平和低复制水平分别给它们在快速有效的药物发现和开发中的有效性带来了巨大的实用限制。能够支持病毒感染的工程化人类肝组织的可用性相对便宜、方便,是评估新的抗病毒疗法和研究丙型肝炎病毒和其他病毒相关病理的理想材料。
这项提案寻求利用工程化三维肝组织领域的专利突破性技术,将其转化为分子病毒学和抗病毒开发的新平台。这项技术成功的关键包括其可伸缩性、重复性,以及产生远远超过以前器官工程尝试的肝组织的既定能力。我们试图确定工程组织是否可以感染一种能够高水平复制的高效肝炎病毒,以及对这种病毒有高度敏感和特异的检测试剂,即丁型肝炎病毒(HDV)。然后,我们将通过确定这些组织支持的丙型肝炎病毒(HCV)感染和复制水平来扩展这项核心技术的潜力。工程肝组织将被接种HDV或丙型肝炎病毒感染血清,或被从感染性克隆转录的RNA转染。免疫组织化学、免疫印迹分析、链特异Northern印迹法复制RNA基因组、连续传代从头产生病毒释放以及对培养上清液进行定量PCR分析将确定是否发生了感染和复制。本提案中详细介绍的项目旨在验证上述假设,并将结果转化为一个有价值的新模型系统,用于研究病毒性肝炎、产生用于研究的病毒和开发抗病毒药物。未来的适应症包括一种独特而宝贵的试剂,用于研究这些病毒生命周期的许多关键方面及其相关的发病机制,以及抗病毒治疗的新方法,包括确定肝细胞亚类的感染潜力,以及其他肝脏疾病,如非酒精性脂肪性肝炎(NASH)、酒精性肝炎、肝纤维化和肝细胞癌(HCC)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian A Naughton其他文献
Brian A Naughton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian A Naughton', 18)}}的其他基金
Predictive Genes Sets For Chemically-Induced Liver Cancer
化学诱导肝癌的预测基因组
- 批准号:
7290454 - 财政年份:2006
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Cancer
化学诱导肝癌的预测基因组
- 批准号:
8050264 - 财政年份:2006
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Cancer
化学诱导肝癌的预测基因组
- 批准号:
7672292 - 财政年份:2006
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Cancer
化学诱导肝癌的预测基因组
- 批准号:
7484222 - 财政年份:2006
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Canc*
化学诱发肝癌的预测基因组*
- 批准号:
7288482 - 财政年份:2006
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Canc*
化学诱发肝癌的预测基因组*
- 批准号:
6666607 - 财政年份:2004
- 资助金额:
$ 29.99万 - 项目类别:
Predictive Genes Sets For Chemically-Induced Liver Canc*
化学诱发肝癌的预测基因组*
- 批准号:
7037824 - 财政年份:2004
- 资助金额:
$ 29.99万 - 项目类别:
Engineered 3-D Human Liver Tissue for Hepatitis Studies
用于肝炎研究的工程 3D 人类肝脏组织
- 批准号:
6693136 - 财政年份:2003
- 资助金额:
$ 29.99万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 29.99万 - 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
- 批准号:
10762827 - 财政年份:2023
- 资助金额:
$ 29.99万 - 项目类别:
Multiplexed enzyme-linked immunosorbent assay workstation for clinical research
用于临床研究的多重酶联免疫吸附测定工作站
- 批准号:
10413539 - 财政年份:2022
- 资助金额:
$ 29.99万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10210940 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
肿瘤相关巨噬细胞成像联合临床研究资源
- 批准号:
10304651 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10592358 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
Co-Clinical Research Resource for Imaging Tumor Associated Macrophages
肿瘤相关巨噬细胞成像联合临床研究资源
- 批准号:
10688045 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别:
Novel NOTCH4 Pathway of Asthma Severity in Urban School Children: Clinical Research Center, Boston Children’s Hospital
城市学童哮喘严重程度的新型 NOTCH4 途径:波士顿儿童医院临床研究中心
- 批准号:
10392449 - 财政年份:2021
- 资助金额:
$ 29.99万 - 项目类别: